Loading...

VRDN VIRIDIAN THERAPEUTICS INC Other Situations 8-K Filing

VRDN

VRDN

VIRIDIAN THERAPEUTICS INC

(VRDN)

2026 8-K

Clinical Trial Results

Financial Results Report

Financial Results Report

Stock Offering Announcement

Cash Position Update

New Funding Agreement

Financial Statements

Financial Statements

Director Appointment

Stock Sale Agreement

Financial Results

CFO Appointment

Positive Trial Results

Financial Results

Positive Trial Results

Financial Results

Investor Presentation

Annual Meeting Approval

Financial Results

Lease Agreement Amendment

Financial Results

Underwriting Agreement

Departure and Appointment o...

Financial Results

Resignation and Bylaws Adop...

Private Placement and Manag...

Appointment of Director

Management Change

Regulation FD Disclosure

Annual Meeting Approval

Financial Results

Departure of Directors

Regulation FD Disclosure

Financial Results

Appointment of President an...

External Links:

On March 30, 2026, Viridian Therapeutics, Inc. announced topline data from a phase 3 clinical trial for their drug elegrobart, aimed at treating thyroid eye disease. The company has also updated their corporate presentation to include this data.

AI Assistant

VIRIDIAN THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.